Changes in bone mineral density after ...
Document type :
Article dans une revue scientifique: Article original
PMID :
Permalink :
Title :
Changes in bone mineral density after allogenic stem cell transplantation.
Author(s) :
Leguy, Diane [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Magro, Leonardo [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Pierache, Adeline [Auteur]
Evaluation des technologies de santé et des pratiques médicales - ULR 2694 [METRICS]
Coiteux, Valérie [Auteur]
Institute for Translational Research in Inflammation - U 1286 [INFINITE]
Yakoub-Agha, Ibrahim [Auteur]
Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Cortet, Bernard [Auteur]
Marrow Adiposity & Bone Lab (MABLab) - ULR 4490
Legroux-Gerot, Isabelle [Auteur]
Service de rhumatologie
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Magro, Leonardo [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Pierache, Adeline [Auteur]
Evaluation des technologies de santé et des pratiques médicales - ULR 2694 [METRICS]
Coiteux, Valérie [Auteur]
Institute for Translational Research in Inflammation - U 1286 [INFINITE]
Yakoub-Agha, Ibrahim [Auteur]
Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Cortet, Bernard [Auteur]
Marrow Adiposity & Bone Lab (MABLab) - ULR 4490
Legroux-Gerot, Isabelle [Auteur]
Service de rhumatologie
Journal title :
Joint Bone Spine
Abbreviated title :
Joint Bone Spine
Volume number :
89
Pages :
105373
Publication date :
2022-03-10
ISSN :
1778-7254
English keyword(s) :
Osteoporosis
Allogenicstemcellstransplantation
Fracture
Bonemineraldensity
Allogenicstemcellstransplantation
Fracture
Bonemineraldensity
HAL domain(s) :
Sciences du Vivant [q-bio]
English abstract : [en]
Objective
Osteoporosis is a complication after allogenic stem cell transplantation (alloSCT). The purpose of this study was to assess changes in bone mineral density (BMD) 6 months and 3 years after alloSCT, as well as ...
Show more >Objective Osteoporosis is a complication after allogenic stem cell transplantation (alloSCT). The purpose of this study was to assess changes in bone mineral density (BMD) 6 months and 3 years after alloSCT, as well as predictors of bone loss. Methods A longitudinal, prospective, single-center study was conducted at Lille University Hospital between 2005 and 2016. Clinical, biological, radiologic (thoracic and lumbar spine) and densitometric (DXA) assessments were carried out at baseline (pre-transplant), 6 months and 3 years. Patients with myeloma were not included. Results Two hundred and fifty-eight patients were included (144 men). Among them, 60.1% had leukemia and 65.8% of them, acute myeloid leukemia. At baseline, 6 months and 3 years, DXA-confirmed that osteoporosis was observed in 17%, 22.8% and 17.5% of the patients, respectively, mainly at the femoral neck. At baseline, 6 months and 3 years, 9 (8.5%), 53 (21.5%) and 38 (16.7%) patients, respectively, were receiving anti-osteoporotic treatment. From baseline to 6-month follow-up, BMD decreased significantly (p < 0.001) at the lumbar spine (−36 [95%CI; −51 to −20] mg/cm2 of hydroxyapatite), femoral neck (−43 [95%CI; −57 to −29] mg/cm2 of hydroxyapatite) and total hip (−53 [95%CI; −68 to −39] mg/cm2 of hydroxyapatite). From 6-month to 3-year follow-up, a significant increase in BMD was observed at the lumbar spine only (+31 [95%CI; 20 to 42] mg/cm2 of hydroxyapatite, p < 0.001). At all 3 sites, changes in BMD did not differ between patients treated or untreated by anti-osteoporotic treatment from 6-month to 3 year follow-up. Incident fractures were found in 4.1% and 5.7% of the patients at 6 months and 3 years, respectively. Between baseline and 6 months, bone loss at all 3 sites was associated with corticosteroid intake. At the total hip, 23.3% of the decrease in BMD from baseline to 6 months was due to an active hematological disease (p < 0.05), a bone marrow stem cells (p < 0.01) and a corticosteroid intake (p < 0.01). Conclusion Our study found evidence of bone fragility in alloSCT patients. Low BMD persisted at the hip 3 years after transplantation due to slower improvement at this site.Show less >
Show more >Objective Osteoporosis is a complication after allogenic stem cell transplantation (alloSCT). The purpose of this study was to assess changes in bone mineral density (BMD) 6 months and 3 years after alloSCT, as well as predictors of bone loss. Methods A longitudinal, prospective, single-center study was conducted at Lille University Hospital between 2005 and 2016. Clinical, biological, radiologic (thoracic and lumbar spine) and densitometric (DXA) assessments were carried out at baseline (pre-transplant), 6 months and 3 years. Patients with myeloma were not included. Results Two hundred and fifty-eight patients were included (144 men). Among them, 60.1% had leukemia and 65.8% of them, acute myeloid leukemia. At baseline, 6 months and 3 years, DXA-confirmed that osteoporosis was observed in 17%, 22.8% and 17.5% of the patients, respectively, mainly at the femoral neck. At baseline, 6 months and 3 years, 9 (8.5%), 53 (21.5%) and 38 (16.7%) patients, respectively, were receiving anti-osteoporotic treatment. From baseline to 6-month follow-up, BMD decreased significantly (p < 0.001) at the lumbar spine (−36 [95%CI; −51 to −20] mg/cm2 of hydroxyapatite), femoral neck (−43 [95%CI; −57 to −29] mg/cm2 of hydroxyapatite) and total hip (−53 [95%CI; −68 to −39] mg/cm2 of hydroxyapatite). From 6-month to 3-year follow-up, a significant increase in BMD was observed at the lumbar spine only (+31 [95%CI; 20 to 42] mg/cm2 of hydroxyapatite, p < 0.001). At all 3 sites, changes in BMD did not differ between patients treated or untreated by anti-osteoporotic treatment from 6-month to 3 year follow-up. Incident fractures were found in 4.1% and 5.7% of the patients at 6 months and 3 years, respectively. Between baseline and 6 months, bone loss at all 3 sites was associated with corticosteroid intake. At the total hip, 23.3% of the decrease in BMD from baseline to 6 months was due to an active hematological disease (p < 0.05), a bone marrow stem cells (p < 0.01) and a corticosteroid intake (p < 0.01). Conclusion Our study found evidence of bone fragility in alloSCT patients. Low BMD persisted at the hip 3 years after transplantation due to slower improvement at this site.Show less >
Language :
Anglais
Audience :
Internationale
Popular science :
Non
Administrative institution(s) :
Université de Lille
Inserm
CHU Lille
Inserm
CHU Lille
Collections :
Submission date :
2024-01-12T02:06:22Z
2024-01-29T13:11:40Z
2024-01-29T13:11:40Z